Drug-eluting stent for unprotected left main coronary artery disease: early and mid-term outcomes.
PCI is increasingly performed in patients with ULMCA disease. The efficacy and safety of drug-eluting stents in ULMCA disease have been reported. To evaluate the early and mid-term clinical outcome of the Percutaneous Coronary Intervention (PCI) with Drug-Eluting stent (DES) in unprotected left main coronary artery (ULMCA) disease patients. PCI with DES was performed with 90 consecutive patients having ULMCA disease between January 2006 and June 2009. At a median follow-up of 22.8 +/- 12.2 months, major adverse cardiac or cerebrovascular events (MACCE) occurred in 11 (12.2%) patients. There were seven (7.8%) deaths including two (2.2%) cardiac deaths and five (5.6%) non-cardiac deaths. There was one MI (1.1%), and four (4.4%) target vessel revascularization. Restenosis in the left main occurred only in two patients (2.2%) and definite stent thrombosis occurred in two patients (2.2%). The present study demonstrates that PCI with Drug-Eluting stent implantation in unprotected left main coronary artery disease is a safe form of treatment and has favorable outcomes.